BR112022013646A2 - Método de tratamento de esplenomegalia - Google Patents

Método de tratamento de esplenomegalia

Info

Publication number
BR112022013646A2
BR112022013646A2 BR112022013646A BR112022013646A BR112022013646A2 BR 112022013646 A2 BR112022013646 A2 BR 112022013646A2 BR 112022013646 A BR112022013646 A BR 112022013646A BR 112022013646 A BR112022013646 A BR 112022013646A BR 112022013646 A2 BR112022013646 A2 BR 112022013646A2
Authority
BR
Brazil
Prior art keywords
splenomegaly
treatment
methods
therapeutic methods
certain embodiments
Prior art date
Application number
BR112022013646A
Other languages
English (en)
Portuguese (pt)
Inventor
Philip Rothbaum Wayne
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of BR112022013646A2 publication Critical patent/BR112022013646A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
BR112022013646A 2020-01-08 2021-01-08 Método de tratamento de esplenomegalia BR112022013646A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
BR112022013646A2 true BR112022013646A2 (pt) 2022-10-04

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013646A BR112022013646A2 (pt) 2020-01-08 2021-01-08 Método de tratamento de esplenomegalia

Country Status (15)

Country Link
EP (2) EP3980069A4 (cg-RX-API-DMAC10.html)
JP (2) JP7771064B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220130151A (cg-RX-API-DMAC10.html)
CN (1) CN114423457A (cg-RX-API-DMAC10.html)
AU (1) AU2021205484A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013646A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164063A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022010592A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220374A (cg-RX-API-DMAC10.html)
IL (1) IL294582A (cg-RX-API-DMAC10.html)
JO (1) JOP20220168A1 (cg-RX-API-DMAC10.html)
MA (3) MA63848B1 (cg-RX-API-DMAC10.html)
MX (1) MX2022008490A (cg-RX-API-DMAC10.html)
TN (1) TN2022000185A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021142257A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12662484B2 (en) 2016-08-17 2026-06-23 Shenzhen Targetrx, Inc. Substituted piperidines as bruton's tyrosine kinase inhibitors
WO2021142257A1 (en) * 2020-01-08 2021-07-15 Telios Pharma, Inc. Methods of treating splenomegaly
US12697333B2 (en) 2020-01-08 2026-08-04 Telios Pharma, Inc. Methods of treating splenomegaly
WO2022266285A1 (en) * 2021-06-16 2022-12-22 Telios Pharma Inc. Treatment of symptoms associated with myeloproliferative neoplasms
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
JP2025527431A (ja) * 2022-08-25 2025-08-22 ビーワン メディシンズ ワン ゲーエムベーハー （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド及びシュウ酸を含む固体形態、その組成物及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3810590A1 (en) * 2018-06-19 2021-04-28 Merck Patent GmbH Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
WO2021142257A1 (en) * 2020-01-08 2021-07-15 Telios Pharma, Inc. Methods of treating splenomegaly

Also Published As

Publication number Publication date
CR20220374A (es) 2023-01-25
AU2021205484A1 (en) 2022-08-18
WO2021142257A1 (en) 2021-07-15
EP4000624A1 (en) 2022-05-25
JP7771064B2 (ja) 2025-11-17
CA3164063A1 (en) 2021-07-15
CO2022010592A2 (es) 2022-10-31
TN2022000185A1 (en) 2024-04-01
JP2023509968A (ja) 2023-03-10
MA57226A1 (fr) 2023-02-28
MX2022008490A (es) 2022-10-13
EP3980069A1 (en) 2022-04-13
MA69153A1 (fr) 2025-07-31
IL294582A (en) 2022-09-01
MA63848B1 (fr) 2024-10-31
JP2026027353A (ja) 2026-02-18
EP3980069A4 (en) 2022-08-17
KR20220130151A (ko) 2022-09-26
CN114423457A (zh) 2022-04-29
MA57226B1 (fr) 2023-06-28
JOP20220168A1 (ar) 2023-01-30
MA63848A1 (fr) 2024-04-30

Similar Documents

Publication Publication Date Title
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
BR112022011228A2 (pt) Formulação farmacêutica líquida, artigo de fabricação, kit e método para tratar uma doença ou distúrbio em um indivíduo
BR112018074152A2 (pt) métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
CO2020014599A2 (es) Métodos para tratar cáncer
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2017002825A (es) Tratamientos medicos a base de anamorelina.
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
EP3922264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
JOP20240197A1 (ar) أشكال متعددة من الأتيكابرانت للاستخدام في علاج اضطراب الاكتئاب الشديد
CR20220071A (es) Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
JOP20220122A1 (ar) طريقة لعلاج سرطان باستخدام خلية مساعدة اصطناعية (aAVC)
BR112018076935A2 (pt) composição, medicamento e método para o tratamento da alopecia induzida por quimioterapia
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
BR112022009881A2 (pt) Inibidores de caspase 6 e usos dos mesmos
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.